US President Donald Trump boards Air Force One before departing Palm Beach International Airport in West Palm Beach, Florida, on March 1, 2026, on his way back to Washington, DC.
Mandel Ngan | Afp | Getty Images
President Donald Trump has thrown his support behind crypto firms in their high-stakes battle with U.S. banks over whether they can offer interest-like returns on stablecoins.
Advertisement
Trump, in a social media post late Tuesday, ratcheted up pressure on banks to relent on the stablecoin yield issue.
That’s the key point of contention holding up passage in Congress of the Clarity Act, which is a companion bill to the Genius Act approved last year, setting up a framework for regulated stablecoins.
“The Genius Act is being threatened and undermined by the Banks, and that is unacceptable,” Trump said in his post. “They need to make a good deal with the Crypto Industry because that’s what’s in best interest of the American People.”
While Trump’s decision to back the crypto industry could sway members of his Republican Party in the GOP-led Congress, it’s unclear whether his support is enough to ensure the bill’s passage. The move also raises fresh questions over potential conflict of interests, as the president and his family have reportedly generated hundreds of millions of dollars in wealth from interests in firms including the crypto platform World Liberty Financial.
The dispute between the industries centers on whether crypto firms like Coinbase can offer yields on stablecoins. While crypto companies see it as a consumer-friendly innovation that will let people earn money on their idle funds, banks have warned that the competing product could siphon trillions of dollars from their industry.
$6.6 trillion threat?
Executives from JPMorgan and Bank of America, the two largest American lenders by assets, have cited a Treasury study that indicated that banks could lose up to $6.6 trillion in deposits if stablecoins offered a yield.
That could destabilize some banks, especially smaller ones, and remove a source of funding for loans to businesses across the country.
Advertisement
Allowing the less-regulated crypto industry to behave like quasi-banks could heighten systemic risk, banks argue. Crypto firms say that the risks are contained and that stablecoins backed by Treasuries will boost demand for U.S. debt.
“It can’t be, you have these people doing one thing without any regulation, and these people doing another,” JPMorgan CEO Jamie Dimon told CNBC’s Leslie Picker on Monday. “If you do that, the public will pay. It will get bad.”
In recent months, the president has hosted a series of White House meetings between the two sides in hopes of brokering a deal, but the banks haven’t relented, according to people with knowledge of the gatherings.
Now, he is explicitly putting his weight behind crypto.
Advertisement
“Americans should earn money on their money,” Trump said in the post. “This industry cannot be taken from the People of America when it is so close to becoming truly successful.”
‘Full of s–t’
That phrasing is similar to language that Coinbase CEO Brian Armstrong has used in interviews. Coinbase is the largest U.S. crypto platform and provides yield to members through what critics in the banking industry call a “loophole” in current regulations.
Armstrong, seen by banks as their main adversary in this dispute, met with Trump at the White House shortly before his social media post Tuesday, according to a person with knowledge of the meeting. That detail was reported earlier by Politico.
Both banks and crypto firms have reasons to support passage of the Clarity Act, but it’s unclear whether that will happen, given the disagreement. Earlier this year, Trump attempted to pressure banks to cap credit card interest rates, but the industry had enough support among both Republicans and Democrats to ward off that threat.
Advertisement
Tensions between Armstrong and banking CEOs have climbed since the Coinbase CEO has publicly called out banks for their opposition to stablecoin yields.
In January, Dimon reportedly told Armstrong he was “full of s–t” at a chance interaction at the World Economic Forum in Davos, Switzerland.
Shares of ImmunityBio Inc. (NASDAQ: IBRX) tumbled nearly 10% in heavy trading Wednesday, reflecting profit-taking after a strong run earlier in the week and broader market caution amid ongoing volatility in biotech stocks.
ImmunityBio
The stock closed at $9.02 on March 4, 2026, down $0.98 or 9.85% from Tuesday’s close of $10.00. Intraday trading saw the price range from a low of $8.93 to a high of $9.59, with volume exceeding 16.5 million shares — solid but below the 35 million-plus average seen in recent sessions. After-hours trading showed modest recovery attempts around $9.01-$9.10.
The pullback followed a volatile period: the shares surged to $10.44 on March 2 amid momentum from positive clinical updates, then eased to $10.00 on March 3 after the company’s full-year 2025 earnings release. Year-to-date in 2026, IBRX has more than quintupled from early lows around $1.83, driven by commercial traction for its flagship therapy ANKTIVA and advancing regulatory milestones.
ImmunityBio reported full-year 2025 results on March 3, highlighting a dramatic 700% year-over-year increase in net product revenue from ANKTIVA (nogapendekin alfa inbakicept-pmln), the IL-15 superagonist approved in April 2024 for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The company expanded ANKTIVA approvals to additional indications, including lung cancer in select markets, and secured commercial partnerships in 33 countries with ongoing label expansion efforts globally.
Analysts responded positively, with Piper Sandler reiterating an Overweight rating and raising its price target to $15, citing strong sales momentum and regulatory progress. Consensus views lean toward “Strong Buy,” with an average 12-month target around $12.60 to $13.06, implying 30-40% upside from current levels. Some forecasts project highs up to $23-$25 if key milestones are met.
Advertisement
Key pipeline advances bolster the outlook. On Feb. 26, 2026, ImmunityBio announced completion of enrollment in the pivotal QUILT 2.005 randomized trial evaluating ANKTIVA plus BCG versus BCG alone in BCG-naïve NMIBC CIS patients. The study enrolled 366 patients ahead of schedule, with an interim analysis requested by the FDA showing statistically significant improvement in duration of complete response for the combination arm and no major safety issues. Full results are expected in Q4 2026, paving the way for a potential Biologics License Application (BLA) submission by year-end to expand ANKTIVA into the first-line setting.
The company also continues discussions with the FDA on a potential resubmission of its supplemental BLA for ANKTIVA in BCG-unresponsive papillary NMIBC. Following a January 2026 Type B End-of-Phase meeting, the agency requested additional supporting information but no new clinical trial. ImmunityBio compiled and planned to submit the data within 30 days, aiming to address prior refuse-to-file concerns without restarting studies.
An expanded access program for recombinant BCG remains active, with over 580 patients enrolled across the U.S., addressing supply shortages and supporting real-world evidence.
Despite the positive momentum, challenges persist. ImmunityBio reported ongoing net losses typical for a clinical-stage biotech, though revenue growth signals commercial viability. Cash position and burn rate remain focal points for investors, with the company emphasizing disciplined capital allocation toward pipeline advancement and global commercialization.
Advertisement
The stock’s 52-week range spans $1.83 to $12.43, with recent highs reflecting optimism around ANKTIVA’s potential to disrupt bladder cancer treatment landscapes — a market with significant unmet needs for durable responses beyond standard BCG therapy.
Market cap hovered near $9-10 billion following the dip, with about 1.03 billion shares outstanding. High short interest and retail investor interest have contributed to volatility, though recent trading has shown more stability tied to fundamentals.
As ImmunityBio eyes Q4 2026 data readouts and potential BLA filings, analysts watch for execution on manufacturing scale-up, partnership expansions, and additional indications. The biotech sector’s sensitivity to interest rates, regulatory timelines, and broader economic factors adds near-term uncertainty, but the company’s progress positions it as a notable player in immunotherapy.
Investors remain divided: bulls see multi-billion revenue potential if ANKTIVA secures broader approvals, while bears caution on competition and execution risks. For now, Wednesday’s decline appears more technical than fundamental, with many viewing the dip as a potential entry point amid the stock’s transformative trajectory.
Thank you, everyone, for joining us. My name is Keith Weiss. I am filling in for Elizabeth Porter, who just had a beautiful baby girl. But actually really excited to be talking with Autodesk, speaking with Janesh Moorjani, CFO of Autodesk. Before Elizabeth took over, I covered Autodesk for a long time, and it’s always been one of my favorite companies.
Excellent. A long, long time ago, I came out of college as an idealistic young man, wanted to be an architect. So I’ve always been pining to be back in this field. And now you’re settling into your role as CFO. You’ve had some time to take a look at the sort of scope of the business. I’m sure you’re excited about it when you kind of came in the door. Now with some time under the belt, maybe you could talk to us about what excites you most about that longer-term potential at Autodesk?
I’m happy to, Keith, and thank you for hosting, by the way, while Elizabeth is out, so we appreciate that. Before we talk about the long-term excitement, what excites me the most in the short term is reading a safe harbor statement. So let me do that first. We may make forward-looking statements during the course of this presentation. Please refer to our SEC filings for information on risks and other factors that may cause our actual results
Buying an engagement ring is one of the most meaningful decisions you will ever make. It represents commitment, love, and a future together — which is why choosing the right jeweller matters just as much as choosing the ring itself.
For generations, couples have visited Hatton Garden, London’s historic jewellery district, known for its exceptional craftsmanship and diamond expertise. However, with so many retailers in one area, identifying the right professional can feel overwhelming.
Why Reputation Matters
When beginning your search, reputation should be your first consideration. Experienced jewellers build trust over time through consistent quality, honest advice, and excellent customer service. Reading detailed reviews and testimonials can give you insight into how previous clients felt about their experience. Did the jeweller take time to explain the process? Were they transparent about pricing? Did they offer guidance without applying pressure?
Choosing from among trusted Hatton Garden jewellers means looking beyond flashy displays and focusing instead on credibility, heritage, and long-term customer satisfaction. A well-established presence in the area often reflects reliability and dedication to craftsmanship.
Transparency and Diamond Certification
A reputable jeweller will always prioritise transparency. This includes providing recognised certification for diamonds and clearly explaining the grading process. Understanding the cut, colour, clarity, and carat weight ensures you know exactly what you are investing in.
Advertisement
Clear communication about pricing is equally important. Rather than presenting a figure without explanation, a professional jeweller will walk you through the value of the stone and the design. This openness builds confidence and allows you to compare options fairly as you explore different engagement ring styles in Hatton Garden.
Considering Modern Diamond Options
In recent years, many couples have explored alternatives to traditionally mined stones. The growing demand for lab grown diamond engagement rings in London reflects a shift towards ethical sourcing and sustainability. These diamonds are visually and chemically identical to natural stones, offering the same brilliance while often being more budget-friendly.
A knowledgeable jeweller will explain the differences between natural and lab grown diamonds in a balanced and informative way. The goal should always be to help you choose a ring that aligns with your values, preferences, and budget — not to steer you in one direction unnecessarily.
The Value of Craftsmanship and Bespoke Design
One of the greatest benefits of choosing Hatton Garden engagement rings is the direct access to highly skilled artisans who specialise in bespoke jewellery creation. Rather than selecting a mass-produced design, couples have the opportunity to shape every detail of their ring, from the choice of setting to the finer elements that give it individuality and character.
Advertisement
Exceptional craftsmanship is about far more than visual appeal. A well-made ring is carefully constructed to ensure strength, balance, and lasting comfort for everyday wear. When you sit down with an experienced jeweller to explore design ideas and examine diamonds up close, the process becomes both personal and reassuring. This level of attention not only enhances the final result but also makes the journey of creating the ring just as special as the proposal itself.
Aftercare and Long-Term Support
An engagement ring is worn every day, so ongoing care is essential. Resizing, cleaning, and maintenance services are important factors to consider before making a purchase. A jeweller who offers reliable aftercare demonstrates confidence in their work and commitment to long-term customer relationships.
Choosing the right jeweller ultimately comes down to trust, transparency, and expertise. By focusing on reputation, quality, and personalised service, you can feel confident that your engagement ring will be both beautiful and enduring, a true symbol of your commitment, crafted with care in one of London’s most respected jewellery destinations.
